Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2012

Open Access 01-09-2012 | review

Current treatment of low grade gliomas

Authors: Martin J. van den Bent, MD, Tom J. Snijders, MD, Jacoline E. C. Bromberg, MD

Published in: memo - Magazine of European Medical Oncology | Issue 3/2012

Login to get access

Abstract

Low grade gliomas affect predominantly young adults, and have a relatively favorable prognosis compared to grade III and grade IV gliomas. The challenge for an optimal management of these patients is to find the balance between an optimal survival and the preservation of neurological function including cognition. Because all medical treatments may induce side effects, in young and nearly asymptomatic patients the choices can be difficult. This review summarizes the current strategies: a watch-and-wait policy, surgery, chemotherapy, and radiotherapy.
Literature
1.
Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56:1098–1104.PubMedCrossRef
2.
Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–18.PubMedCrossRef
3.
Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in suspected versus proven low-grade gliomas. Neurology. 2001;56:618–23.PubMedCrossRef
4.
Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442–8.PubMedCrossRef
5.
Surma-aho O, Niemelä M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285–90.PubMedCrossRef
6.
Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.PubMedCrossRef
7.
Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg. 1993;79:533–6.PubMedCrossRef
8.
Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.PubMedCrossRef
9.
Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011;13:307–16.PubMedCrossRef
10.
Brasil CG, Ciccarelli O, Altmann DR, et al. Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. 2009;253:505–12.CrossRef
11.
Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol. 2009;11:176–82.PubMedCrossRef
12.
Van Den Bent MJ, Afra D, De Witte O, et al. Long term results of EORTC study 22845: a randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet. 2005;366:985–90.PubMedCrossRef
13.
Taphoorn MJB, Klein Schiphorst A, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48–54.PubMedCrossRef
14.
Correa DD, Shi W, Thaler HT, et al. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86:321–7.PubMedCrossRef
15.
Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet. 2002;360:1361–8.PubMedCrossRef
16.
Rees J, Watt H, Jager HR, et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2008;21(1):54–64.
17.
Soffietti R, Borgogne M, Ducati A, et al. Efficacy of radiation therapy on seizures in low-grade astrocytomas. Neuro-Oncology. 2005;7:389 (abstract #422, abstr).
18.
Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108:227–35.PubMedCrossRef
19.
Pignatti F, Van Den Bent MJ, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.PubMedCrossRef
20.
Shaw E, Arusell RM, Scheithauer B, et al. A prospective randomized trial of low versus high dose radiation in adults with a supratentorial low grade glioma: initial report of a NCCTG-RTOG-ECOG study. J Clin Oncol. 2002;20:2267–76.PubMedCrossRef
21.
Brown PD, Buckner JC, O’Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiation Oncol Biol Phys. 2004;59:117–25.CrossRef
22.
Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109:817–24.PubMedCrossRef
23.
Daniels TB, Brown PD, Felten SJ, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72–51. Int J Radiat Oncol Biol Phys. 2011;81:218–24.PubMedCrossRef
24.
Floeth FW, Pauleit D, Sabel M, et al. Prognostic Value of O-(2–18 F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. J Nucl Med. 2007;48:519–27.PubMedCrossRef
25.
Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109:835–41.PubMedCrossRef
26.
Gunnarsson T, Olafsson E, Sighvatsson V, et al. Surgical treatment of patients with low-grade astrocytomas and medically intractable seizures. Acta Neurol Scand. 2002;105:289–92.PubMedCrossRef
27.
Duffau H, Capelle L, Lopes M, et al. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir (Wien). 2002;144:563–72.CrossRef
28.
Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120:719–29.PubMedCrossRef
29.
Stockhammer F, Misch M, Helms HJ, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21(3):194–7.PubMedCrossRef
30.
Duffau H, Lopes M, Arthuis F, et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985–96) and with (1996–2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry. 2005;76:845–51.PubMedCrossRef
31.
Claus E, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magentic resonance image guidance. Cancer. 2005;103:1227–33.PubMedCrossRef
32.
Chang EF, Clark A, Smith JS, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011;114:566–73.PubMedCrossRef
33.
Karim ABMF, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 2284. Int J Radiation Oncol Biol Phys. 1996;36:549–56.CrossRef
34.
Shaw EG, Wang M, Coons S, et al. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). Proc Am Soc Clin Oncol. 2008;26 (abstract 2006, abstr).
35.
Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12:1078–82.PubMedCrossRef
36.
Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831–6.PubMedCrossRef
37.
Van Den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.PubMedCrossRef
38.
Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95:87–93.PubMedCrossRef
39.
Buckner JC, Gesme D, O’Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–5.PubMedCrossRef
40.
Biemond-ter Stege E, Kros JM, de Bruin HG, et al. Treatment of low grade oligodendroglial tumors with PCV chemotherapy. Cancer. 2005;103:802–9.CrossRef
41.
Taal W, Dubbink HJ, Zonnenberg CB, et al. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol. 2011;13:235–41.PubMedCrossRef
Metadata
Title
Current treatment of low grade gliomas
Authors
Martin J. van den Bent, MD
Tom J. Snijders, MD
Jacoline E. C. Bromberg, MD
Publication date
01-09-2012
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2012
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0014-3

Other articles of this Issue 3/2012

memo - Magazine of European Medical Oncology 3/2012 Go to the issue

short review

Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology

short review

ASH 2011—current developments in AML

short review

Treating T-cell lymphoma: is there a light at the end of the tunnel?

short review

New drugs for head and neck cancer

short review

New developments in MDS

short review

Brief update on recent developments in CML
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits